Goldman Sachs Downgrades Vertex (VRTX) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Vertex Reports First Quarter 2016 Financial Results
April 27, 2016 4:01 PM EDT-First quarter 2016 cystic fibrosis product revenues of $394 million; $223 million for ORKAMBI® (lumacaftor/ivacaftor) and $171 million for KALYDECO® (ivacaftor)-
-Provides 2016 guidance for ORKAMBI product revenues of $1.0 to $1.1 billion; increases 2016 guidance for KALYDECO product revenues to $685 to $705 million-
-Provides update on approved CF medicines and pipeline of investigational medicines-
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended March 31, 2016 and provided an update on its approved CF medicines and other investigational medicines. Vertex also... More
